Join Ingrid Mayer, MD, and Ingrid Meszoely, MD, as they present their multidisciplinary expertise on a range of cases pertaining to Breast Cancer - Advanced Disease.
Breast cancer is the most commonly diagnosed cancer in American women. The American Cancer Society estimates that 235,030 women will be diagnosed with breast cancer and 40,430 will die of the disease in the United States in 2014.
Patients with metastatic breast cancer consist of a heterogeneous group whose clinical outcome varies depending on tumor factors, such as hormone-receptor and HER2 status and other factors, such as comorbidity and age, and anatomical site of disease. All patients with metastatic breast cancer receive systemic therapy. In certain circumstances, treatment may also involve surgery or radiation. Systemic therapy includes the use of endocrine therapy, chemotherapy, and/or HER-2 targeted therapy. Better understanding of the metastatic pathway in breast cancer has led to development and approval of several new systemic therapy agents in this setting such as everolimus, pertuzumab, and ado-trastuzumab emantansine.
Based on the drug new approvals and emerging clinical trial data, the National Comprehensive Cancer Network (NCCN) Guidelines for Breast Cancer have included new recommendations for patients with HER-2 positive metastatic breast cancer.
Selecting the optimal systemic therapy depends on the tumor burden, patient symptoms, and several other clinical factors. It is important to help clinicians understand the available and emerging clinical data and apply these in selecting the most efficient treatment strategy for patients with metastatic breast cancer of specific tumor types.
NCCN is offering a series of twelve multidisciplinary case-based webinars on a variety of topics, including Lymphoma: Mantle Cell, Lymphoma: CLL/SLL, Chronic Phase CML, Multiple Myeloma, Breast Cancer: Adjuvant Systemic Therapy, Breast Cancer: Advanced Disease, Lung Cancer: Biomarker Driven Advanced Disease, Lung Cancer: Locally Advanced NSCLC: Stage IIIA Management, Metastatic Colorectal Cancer, Prostate Cancer: Castrate Resistant, Melanoma, and Kidney Cancer. Each webinar will be facilitated by two faculty members providing multidisciplinary perspectives. A different topic will be presented each month for twelve months (June 2014 until June 2015).
The NCCN Guidelines are a set of step-by step evidence-based, consensus-driven recommendations that ensure that patients receive preventive, diagnostic treatment, and care that is most likely to lead to optimal outcomes. The NCCN recommendations are applicable to about 95% of patients. Clinicians need to consider the current clinical status of the patient, including general health, disease specifics, concomitant conditions, current and previous therapies, and the patients how to best apply appropriate standard of care including identifying circumstances where appropriate management requires adapting the NCCN Guidelines to the needs of the individual. This activity series will discuss the specific recommendations in the NCCN Guidelines as well as unique patient circumstances that impact how the NCCN Guidelines might be best applied.
Thursday, June 12, 2014 3:30 PM - 4:30 PMEastern Time
NCCN Meetings Department
World Time Zone MapSee when meeting occurs in other time zonesWorld Time Zone Map
NCCN.org – For Clinicians | NCCN.org/patients – For Patients
National Comprehensive Cancer Network | 275 Commerce Drive | Suite 300 | Fort Washington | PA | 19034 | US | 215.690.0300